Pfizer Inc. (PFE)
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.
Pfizer Stock: Wall Street Sees a Rebound, Here's Our Price Target
Our 24/7 Wall St. price target for Pfizer (NYSE:PFE | PFE Price Prediction) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07.
Pfizer: Patient Investors Will Be Rewarded
Pfizer remains significantly undervalued, demonstrating robust profitability and offering an attractive forward dividend yield above 6%. PFE's diversified product roadmap and disciplined capital allocation help offset LOE uncertainties and COVID revenue declines, stabilizing business variability. Oncology pipeline progress, bolstered by the Seagen acquisition, provides credible growth pathways beyond early clinical stages, anchoring the long-term growth optionality.
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
Dividend investors have had plenty to cheer in 2026. Pfizer (NYSE:PFE | PFE Price Prediction) is up 19.3% year to date, Chevron (NYSE:CVX) has surged 38.76%, and AbbVie (NYSE:ABBV) has added 19.16%.
Yield Hunters Are Swarming This 6.3%-Dividend Stock—And Big-League Hedge Funds are Quietly Buying the Dip
Big-league hedge funds have been taking interest in shares of Pfizer (NYSE:PFE | PFE Price Prediction) of late, with recent 13F filings revealing significant buying activity among the smart money crowd.
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far.
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.
Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff
Pfizer remains a cautious Buy, trading near intrinsic value with an expected 10% annual return, primarily from its high dividend yield. PFE faces significant headwinds: a looming patent cliff, a stretched balance sheet, and questions about the sustainability of its dividend and growth prospects. Management projects high single-digit revenue CAGR post-2028, driven by acquisitions, pipeline progress, and aggressive cost-saving initiatives, though analysts remain skeptical.
Valneva: The Lyme Royalty Transition Changes The Earnings Model
Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and milestone model, anchored by its Lyme disease partnership with Pfizer. Recent financials were impacted by IXCHIQ-related charges, but restructuring is improving the expense base and cash runway, with about three years of funding at current burn rates. Pfizer's Lyme vaccine candidate, with 73% efficacy and EMA validation, positions VALN for significant royalty and milestone income if approved and successfully commercialized.
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug was taken off the market in 2021.
